Back to Journals » OncoTargets and Therapy » Volume 13

FOXN4 Inhibits Breast Cancer Progression by Direct Activation of P53 [Retraction]

Authors Ye H, Duan M

Received 9 November 2020

Accepted for publication 9 November 2020

Published 16 November 2020 Volume 2020:13 Pages 11741—11742

DOI https://doi.org/10.2147/OTT.S291183



Ye H, Duan M. Onco Targets Ther. 2020;13:71—81.


The Editor and Publisher of OncoTargets and Therapy wish to retract the published article.


The journal was notified of similarities between the published paper and another article published in the journal Gene:

● Identification of FOXN4 as a tumor suppressor of breast carcinogenesis via the activation of TP53 and deactivation of Notch signaling (https://doi.org/10.1016/j.gene.2019.144057).


In particular, it was noted both articles presented similar data in Table 1 and shared nearly identical reference lists. The article was submitted and accepted by OncoTargets and Therapy prior to publication in  Gene, however it was noted the article was submitted to Gene prior to publication in OncoTargets and Therapy.


The authors were unable to provide a satisfactory explanation for the similarities and were also unable to provide satisfactory raw data for the study.


Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.


The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.

 

This retraction relates to this paper

 

Creative Commons License © 2020 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.